Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.46 +0.54 (+2.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
A fundamental analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is showing decent growth, but is still valued reasonably.
CATALYST PHARMACEUTICALS INC could be undervalued. NASDAQ:CPRX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your... 
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Why NASDAQ:CPRX qualifies as a high growth stock.
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:CPRX.
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Exploring NASDAQ:CPRX's high growth characteristics.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX). 
Via Chartmill
For those who appreciate value investing, CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a compelling option with its solid fundamentals.
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock.
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies? 
Via Chartmill
Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock?
Based on a technical and fundamental analysis of NASDAQ:CPRX we are exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout. 
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? 
Via Chartmill
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
The drugmaker confirmed there's a strong market for two of its treatments. 
Via The Motley Fool
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
Via Benzinga
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s CANSLIM characteristics. 
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
CATALYST PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:CPRX showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.
Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued. 
Via Chartmill
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
NASDAQ:CPRX: good value for what you're paying.
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
Unlocking the high Growth Potential of NASDAQ:CPRX.
Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s high Growth Prospects. 
Via Chartmill
NASDAQ:CPRX, an undervalued stock with good fundamentals.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.